EMEA-002168-PIP01-17-M04
Key facts
| Invented name |
Zolgensma
|
| Active substance |
Onasemnogene abeparvovec
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0015/2022
|
| PIP number |
EMEA-002168-PIP01-17-M04
|
| Pharmaceutical form(s) |
Solution for injection/infusion
|
| Condition(s) / indication(s) |
Treatment of spinal muscular atrophy
|
| Route(s) of administration |
|
| Contact for public enquiries |
Novartis Gene Therapy EU Limited
paediatric.enquiries@novartis.com +41 613241111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|